Last reviewed · How we verify
NCT03927014: thiols&PE
Thiol/Disulphide Homeostasis and Preeclampsia
trial testing thiol/disulfide levels in Preeclampsia in 100 participants. Completed in 5 February 2020.
1 January 2020
Quick facts
| Lead sponsor | Cengiz Gokcek Women's and Children's Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 25 April 2019 |
| Primary completion | 1 January 2020 |
| Estimated completion | 5 February 2020 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- thiol/disulfide levels
Conditions studied
- Preeclampsia — all drugs for Preeclampsia →
Sponsor
Cengiz Gokcek Women's and Children's Hospital
Who can join
Adults 18 to 40, female only, with Preeclampsia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Objective: To evaluate serum evaluate thiol/ disulfide levels in preeclampsia and address its relationship with its severity. Methods: This prospective study will include 50 pregnancies complicated with preeclampsia and 50 healthy pregnancies. The blood for analysis will obtain at the admission and serum thiol/ disulfide levels will measure using commercially available reagent kits. The continuous values were evaluated using Student's t-test, and categorical values were evaluated using the Chi-square test. P values \< .05 were accepted as significant.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03927014
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Preeclampsia
Currently open trials in the same condition.
- NCT06953115 — Vagal Stimulation Therapy and Preeclampsia · NA · recruiting
- NCT06333652 — Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders · Phase 2 · recruiting
- NCT07282171 — A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Parti · Phase 1 · recruiting
- NCT07345845 — MR and Inflammation After Preeclampsia · EARLY_PHASE1 · active not recruiting
- NCT07041281 — Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories · Phase 2 · recruiting
Other Cengiz Gokcek Women's and Children's Hospital trials
Trials by the same sponsor.
- NCT04800705 — Levels of Selected Macroelements in Premature Ovarian Insufficiency · unknown
- NCT04767451 — Levels of Selected Microelements in Premature Ovarian Insufficiency · unknown
- NCT04641624 — sFlt- 1, PIGF, and Niacin Levels in Women With Premature Ovarian Insufficiency · completed
- NCT04588220 — Melatonin, Soluble Urokinase-type Plasminogen Activator Receptor, and Orosomucoid 2 Levels in PPROM · unknown
- NCT04523233 — Metals/Vitamins Levels in NTD · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03927014 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cengiz Gokcek Women's and Children's Hospital
- Last refreshed: 11 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03927014.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing